Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07440225 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

Study acronym: MALBEC
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 124 → 132 locations
  2. Trial sites expanded: 117 → 124 locations
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 10 of 10 entries
  3. Trial sites expanded: 110 → 117 locationsv11
  4. Trial sites expanded: 97 → 110 locationsv10
  5. Trial sites expanded: 91 → 97 locationsv9
  6. Trial sites expanded: 87 → 91 locationsv8
  7. Trial sites expanded: 71 → 87 locationsv7
  8. Trial sites expanded: 42 → 71 locationsv6
  9. Trial sites expanded: 30 → 42 locationsv5
  10. Trial sites expanded: 20 → 30 locationsv4
  11. Study sites revised (20)v3
  12. Recruitment opened
    • Trial sites expanded: 0 → 20 locations
    • Start date changed from estimate of Mar 31, 2026 to Mar 27, 2026
    v2
  13. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
Trial Details
NCT Number NCT07440225
Lead Sponsor EyeBiotech Ltd.
Conditions
(from sponsor)		 Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Related terms Choroidal Neovascularization, Macular Degeneration, Wet Macular Degeneration
Enrollment 960 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov